Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Several other research analysts also recently issued reports on the company. TheStreet downgraded Supernus Pharmaceuticals from a b- rating to a c+ rating in a research note on Thursday, August 29th. Stifel Nicolaus set a $55.00 price target on Supernus Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, August 7th. Mizuho reaffirmed a buy rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, August 7th. Jefferies Financial Group downgraded Supernus Pharmaceuticals from a buy rating to a hold rating and cut their price target for the stock from $46.00 to $23.00 in a research note on Wednesday. Finally, BidaskClub raised Supernus Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $46.50.

NASDAQ:SUPN traded up $0.57 during mid-day trading on Wednesday, hitting $21.72. The stock had a trading volume of 1,010,300 shares, compared to its average volume of 579,923. Supernus Pharmaceuticals has a twelve month low of $19.35 and a twelve month high of $49.25. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The stock has a 50-day simple moving average of $26.80 and a two-hundred day simple moving average of $30.29. The company has a market capitalization of $1.53 billion, a PE ratio of 10.60, a PEG ratio of 1.02 and a beta of 1.63.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.05). Supernus Pharmaceuticals had a net margin of 25.92% and a return on equity of 21.80%. The business had revenue of $102.14 million during the quarter, compared to analyst estimates of $108.70 million. During the same period last year, the business posted $0.52 EPS. Supernus Pharmaceuticals’s revenue was down .8% compared to the same quarter last year. Sell-side analysts predict that Supernus Pharmaceuticals will post 2.14 EPS for the current fiscal year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In related news, CEO Jack A. Khattar acquired 7,200 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average price of $26.39 per share, for a total transaction of $190,008.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 6.57% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in SUPN. Municipal Employees Retirement System of Michigan grew its stake in Supernus Pharmaceuticals by 2.2% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 15,650 shares of the specialty pharmaceutical company’s stock worth $518,000 after buying an additional 330 shares during the last quarter. Bridge City Capital LLC grew its stake in shares of Supernus Pharmaceuticals by 0.5% in the second quarter. Bridge City Capital LLC now owns 69,000 shares of the specialty pharmaceutical company’s stock worth $2,283,000 after purchasing an additional 338 shares in the last quarter. Renaissance Group LLC grew its stake in shares of Supernus Pharmaceuticals by 3.8% in the third quarter. Renaissance Group LLC now owns 10,496 shares of the specialty pharmaceutical company’s stock worth $288,000 after purchasing an additional 380 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Supernus Pharmaceuticals by 2.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 20,639 shares of the specialty pharmaceutical company’s stock worth $683,000 after purchasing an additional 400 shares in the last quarter. Finally, Baltimore Washington Financial Advisors Inc. grew its stake in shares of Supernus Pharmaceuticals by 0.9% in the second quarter. Baltimore Washington Financial Advisors Inc. now owns 45,033 shares of the specialty pharmaceutical company’s stock worth $1,490,000 after purchasing an additional 420 shares in the last quarter. 99.14% of the stock is currently owned by hedge funds and other institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Further Reading: What does an outperform rating mean?

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Leave a Reply

Your email address will not be published. Required fields are marked *

*